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Abstract Erythropoietic protoporphyria (EPP) is charac-
terised by excess production of free protoporphyrin from
the bone marrow, most commonly due to deficiency of the
enzyme ferrochelatase. Excess protoporphyrin gives rise to
the cutaneous photosensitivity characteristic of the disease,
and in a minority of patients leads to end-stage liver disease
necessitating liver transplantation (LT). There is limited
information regarding the timing, impact and long-term
outcome of LT in such patients, thus we aimed to identify
the indications and outcomes of all transplants performed
for EPP in the UK using data from the UK Transplant
Registry. Between 1987 and 2009, five patients underwent
LT for EPP liver disease. Median follow-up was 60 months,
and there were two deaths at 44 and 95 months from causes
unrelated to liver disease. The remaining recipients are alive
at 22.4 years, 61 months and 55 months after transplant. A
high rate of postoperative biliary stricturing requiring
multiple biliary interventions was observed. Recurrent
EPP-liver disease occurred in 4/5 (80%) of patients but
graft failure has not been observed. Given the role of biliary
obstruction in inducing EPP-mediated liver damage, we
suggest that consideration should be given for construction
of a Roux loop at the time of transplant. Thus we
demonstrate that although EPP liver transplant recipients
have a good long-term survival, comparable to patients
undergoingLTforotherindications,biliarycomplicationsand
disease recurrence are almost universal, and bone marrow
transplantation should be considered where possible.
Abbreviations
ALAS2 Aminolaevulinic acid synthase 2
BMT Bone marrow transplantation
EPP Erythropoietic protoporphyria
ERCP Endoscopic retrograde cholangiopancreatography
ESLD End stage liver disease
INR International normalised ratio
LT Liver transplantation
MARS Molecular adsorbent recycling system
MELD Model for end stage liver disease
NHS National Health Service
UNOS United Network for Organ Sharing
XLDPP X-linked dominant protoporphyria
Introduction
The erythropoietic porphyrias include two disorders char-
acterised by excess production of free protoporphyrin from
the bone marrow, due to either deficiency of the enzyme
ferrochelatase (erythropoietic protoporphyria; EPP
MIM#177000) (Elder et al. 2009;Todd 1994), or a gain of
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(ALAS2) (X-linked dominant protoporphyria; XLDPP
MIM#300752). The latter is less common (Elder et al.
2009) but appears to carry a higher risk of liver disease
(Whatley et al. 2008). Photo-excitation of protoporphyrin in
the skin leads to the painful photosensitivity characteristic
of the disease (Todd 1994). Increased biliary protoporphyrin
excretion exerts toxic effects on hepatobiliary structure and
function (Avner et al. 1981;Morton et al. 1988), although
advanced, progressive liver disease manifests in only a small
minority (Anstey and Hift 2007;Doss and Frank, 1989;
Meerman 2000). As yet there are no modifiable risk factors
for the development of liver disease in protoporphyria which
would allow those at highest risk to be closely monitored.
However, the risk appears to be increased in the 4% of
patients who are homozygotes or compound heterozygotes
for rare ferrochelatase (FECH) mutations (Elder et al. 2009;
Whatley et al. 2004) and in XLDPP (Whatley et al. 2008). A
cross-sectional study of protoporphyria in the UK has
calculated the minimum prevalence of EPP in the UK
to be 1:143,000 (Holme et al. 2006). Of the 223 UK
patients recruited to the study, 4 (1.8%) had severe liver
disease that had required management in a liver unit
(Holme et al. 2006). Although medical management is the
mainstay of treatment for the great majority of patients,
liver transplantation should be considered for patients with
end-stage liver disease.
Mechanisms of protoporphyrin hepatotoxicity in EPP in
experimental models include formation of cytotoxic bile
which damages biliary epithelium leading to biliary fibrosis
(Meerman et al. 1999), impaired bile formation (Avner et
al. 1981) and alterations in hepatic membrane enzyme
activity (Avner et al. 1983).
Our group has previously reported the short term follow
up of two patients undergoing liver transplantation for EPP in
asi ng lece nt re(H er be rtetal .1991;Seth et al. 2007). No other
adult liver transplants have been reported for this indication
in the UK. Using data from the UK Transplant Registry
maintained by NHS Blood and Transplant on behalf of the
transplant community, we here describe a larger national
series with longer term follow up which includes all liver
transplants performed for EPP in the UK from 1987-2009.
Methods
This is a retrospective study of all known patients in the UK
transplanted for EPP liver disease. They were identified by
searching the UK Transplant Registry. The diagnosis of EPP
was made byclinicalfeatures,elevatederythrocyte andplasma
free protoporphyrin levels and histology of explanted liver.
Data collected included patient demographics, preop-
erative laboratory results and clinical status, date of
transplant, long term graft and patient survival, cause of
death where relevant, and immunosuppressive protocol.
Postoperative complications were also recorded. Missing
data were obtained where possible by review of case
notes or communication with the respective liver unit.
Patient survival was defined as the time between initial
transplant and patient death.
The MELD (model for end-stage liver disease) score was
calculated for each patient in this study to assess the
severity of liver disease. The MELD is a validated marker
of risk of early death without transplantation (Neuberger et
al. 2008), and is used by the United Network for Organ
Sharing (UNOS) to determine priority for adult organ
allocation. The score is calculated using the variables of
serum bilirubin, international normalised ratio (INR) and
creatinine, and the survival benefit for transplantation is for
patients with a MELD score >16 (Neuberger et al. 2008).
Results
Between 1987 and 2009, five patients were identified to
have undergone liver transplantation for protoporphyria in
the UK. Erythrocyte porphyrin biochemistry results were
available for four patients and consistent with the diagnosis
of EPP (increased free protoporphyrin, normal zinc proto-
porphyrin fraction). Transplants were performed across
three different liver transplant centres.
Three (60%) patients were male, and median age at
transplant for EPP was 40 years (range 17-59 years). Two
transplants took place in 1987 and 1992, and the remaining
three between 2003 and 2005 (Table 1).
Biliary reconstruction at the time of transplant was
performed using a duct-to-duct anastomosis in the four
(80%) patients for whom these data were available. All
patients were commenced on combined calcineurin-
inhibitor based immunosuppressive therapy, with the
individual protocols reflecting the more recent trend
towards use of tacrolimus in place of cyclosporine in such
regimens. Two (40%) of EPP transplant recipients required
readmission during the first year due to acute rejection, one
of whom also developed evidence of chronic rejection.
Indication for transplant
In EPP, the indication for liver transplantation was the
development of protoporphyrin-induced end-stage liver
disease, defined by liver histology and markedly abnormal
liver function. Median MELD score at the time of listing
was 22 (range 19-25), which is comparable to adults
undergoing liver transplantation for other indications
(Freeman 2008). In our centre, one patient also suffered
severe photosensitivity, gallstones, and recurrent acute
540 J Inherit Metab Dis (2011) 34:539–545crises of abdominal pain and hepatitis requiring regular
treatment with both hemin and opiates. Recurrent red cell
transfusions in this patient, performed to maintain haemo-
globin and thus reduce the drive for haem synthesis and
consequent protoporphyrin production, necessitated addi-
tional desferrioxamine therapy in order to prevent iron
overload. With no evidence of overt blood loss, the chronic
low-grade anaemia observed here may have been related to
haemolysis, iron deficiency and/or chronic disease. A
second patient at our centre presented with photosensitive
dermatitis, and underwent transplantation four years after
diagnosis for end-stage EPP-liver disease after a rapid
deterioration with encephalopathy and jaundice.
Explant histology
Explant histology was available for three patients. One
report described a macroscopically hard and dark liver
typical of EPP, with histological analysis revealing early
micronodular cirrhosis, large amounts of brown pigment in
Kupffer cells, and dilated biliary canaliculi, hepatocytes and
bile ducts. A second liver explant was macroscopically dark
brown and nodular, with microscopic analysis revealing early
cirrhosis with a biliary pattern, and grade 3 parenchymal
siderosis. Protoporphyrin crystals were present with pigment
in hepatocytes, Kupffer cells and bile canaliculi. The third
liver explant was reported to be macroscopically enlarged and
greenish-black in colour. Histology revealed cirrhosis with
marked cholestasis, grade 1 siderosis, and the presence of
brown pigment deposits in bile ducts, Kupffer cells and
hepatocytes with red birefringence consistent with EPP.
Survival
Median follow-up was 60 months. Two deaths occurred at
44 and 95 months, and three patients remain alive at
22.4 years, 61 months and 55 months after transplant. One
patient died from cerebral tuberculosis; the other cause of
death was unspecified but not related to the liver.
Disease recurrence
In EPP liver transplantation does not alter the excessive
production of protoporphyrin in erythroid cells from the
bone marrow. Recurrence of liver damage is therefore
common, and histologically proven recurrent EPP liver
disease occurred within 2 years of transplant in four (80%)
of these patients. Two had recurrence by 4 months, and one
as early as 24 days post-transplant. Recurrence was usually
associated with abnormal liver function and complications
such as biliary sludge/stones, however graft failure from
recurrent disease has not yet been observed in this cohort.
Biopsy in recurrent disease typically showed reaccumulation
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J Inherit Metab Dis (2011) 34:539–545 541of protoporphyrin crystals, pigmentation, and cholestasis,
with or without fibrosis. Absence of any features of recurrent
EPP liver disease in a single patient was confirmed by biopsy
16 years post-transplant. This individual had been taking the
bile acid sequestrant cholestyramine throughout the period of
follow-up.
As the only potentially curative treatment for this
disorder, bone marrow transplantation (BMT) was per-
formed in one patient with recurrent EPP liver disease, in
whom neither dialysis nor molecular adsorbent recycling
system (MARS) had demonstrated a beneficial effect on
erythrocyte protoporphyrin levels. Although BMT did lead
to cure of the EPP, as demonstrated by a dramatic fall in
erythrocyte protoporphyrin levels and a fully functioning
liver, this patient unfortunately died 2.7 years later from
cerebral tuberculosis. BMT has been considered but not
undertaken in two other patients in this cohort, one of
whom died from unrelated causes.
Complications
Biliary complications, primarily stones, sludge and strictures,
are frequently observed in EPP. Four (80%) of the patients in
this cohort experienced such complications after liver
transplantation, which were usually evidenced biochemically
by worsening liver function of a cholestatic nature. All of
these patients have required multiple interventions for biliary
strictures and/or stones/sludge (Table 1).
Second-degree skin burns due to peri-operative light
exposure were observed in one patient, who also experi-
enced a post-operative biliary leak and later required ERCP
and sphincterotomy for biliary sludge/stone related chole-
stasis. This patient eventually underwent a biliary Roux-en-
Y reconstruction 14.5 years post-transplant following an
episode of cholangitis related to a common bile duct stone
and anastomotic stricture. Liver biopsy repeated several
months after this intervention confirmed disappearance of
the previously observed features of chronic biliary obstruc-
tion, and no further biliary complications have occurred in
the subsequent 8 years of follow-up. Another patient with
particularly severe recurrent EPP-mediated liver damage
developed a post-transplant biliary anastomotic stricture
with consequent deterioration in cutaneous symptoms, liver
function tests and erythrocyte protoporphyrin levels. ERCP
with dilatation and stenting has been performed on several
occasions with notable improvement, and consideration
given to the possibility of definitive biliary reconstructive
surgery. Four years after transplantation an episode of late
acute rejection in this patient, in the setting of worsening
EPP-induced liver damage with biliary complications, led
to a rise in bilirubin to over 450 μmol/L. Liver biopsy
showed evidence of chronic hepatitis with moderate
fibrosis, biliary features and protoporphyrin crystals con-
sistent with significant EPP-induced liver damage. Manual
red cell exchange was successfully undertaken in this
individual (Fig. 1), with marked biochemical and symp-
tomatic improvement. In addition to red cell exchange,
haemoglobin levels were maintained >12 g/dl (Fig. 1).
Of the three remaining patients, two individuals with
biopsy-proven recurrent EPP liver disease required recur-
rent admissions for ERCP to treat biliary complications
(stricture/sludge/stones). One of these patients was being
considered for BMT due to iron overload at the time of her
death, which occurred at 44 months post-transplant from a
cause unrelated to the liver.
The remaining patient had biopsy-proven EPP-liver
disease recurrence by day 24 post-transplant. Although no
biliary complications were observed, this patient underwent
bone marrow transplantation (BMT) one year after LT,
following which a significant fall in plasma porphyrin
levels was observed together with a fully functioning liver,
suggesting this was indeed curative. However complications
of immunosuppression and sepsis eventually culminated in
death 2.7 yrs after BMT.
Discussion
In this study we report a long-term series of patients
undergoing liver transplantation for EPP in the UK, which
includes all adult patients transplanted for this indication
between 1987 and 2009.
3 x manual
exchange transfusions
Fig. 1 Relationship between haemoglobin and disease activity and
effect of manual red cell exchange on erythrocyte protoporphyrin
levels in a patient with post-transplant EPP recurrence. Erythrocyte
protoporphyrin levels decreased rapidly following LT in 2005, before
rising again in association with disease recurrence. Reductions in
haemoglobin correspond with increasing erythrocyte protoporphyrin
levels as a result of the increased drive for haem synthesis,
highlighting the importance of maintaining an adequate haemoglobin
level>~12 g/dl. Repeated manual red cell exchange transfusions in
2009 resulted in a rise in haemoglobin and reduction in erythrocyte
protoporphyrin levels associated with symptomatic improvement. The
standard protocol involved removal of 250 ml of blood via a central vein
and replacement with 250 ml normal saline and 1 unit of packed red cells
542 J Inherit Metab Dis (2011) 34:539–545In contrast to acute porphyrias, where the majority of
severely affected patients are female, in this study there was
no significant gender difference in patients undergoing
transplantation for EPP. These findings are consistent with
the US series of 20 patients where a 3:2 male:female ratio
was observed(McGuire et al. 2005). It remains possible that
this slight male predominance may reflect the increased
frequency of XLDPP in males, which may also be more
likely to cause hepatopathy, (Elder et al. 2009) although
ferrochetolase gene abnormalities were present in each of
the ten patients in this study in whom DNA analysis was
performed. (McGuire et al. 2005).
Median age at transplant was 40 years which is
considerably younger than the traditional elective liver
transplant population (van der Meulen et al. 2007). Three
EPP recipients (60%) remain alive at between 55 months
and 22.4 years and there were two deaths at 44 and
95 months from causes not directly related to the porphyria.
This data is again in keeping with reports of patients
transplanted for this indication in the US, where a 69%
patient and graft survival was seen (McGuire et al. 2005). It
has been reported that liver disease is more prevalent in
patients with autosomal recessive EPP (Elder et al. 2009;
Whatley et al. 2008) and XLDPP (Whatley et al. 2008). In
this cohort, all patients had an erythrocyte protoporphyrin
screen to identify the presence of free and or zinc
protoporphyrin, and XLDPP was considered unlikely
because of the absence of the typical pattern of increased
zinc and free protoporphyrin associated with this disorder.
Although the proportion of transplanted patients with
XLDPP is not presently known, and this subgroup of
patients does warrant more careful monitoring, it is likely
that these patients account for a minority of the liver disease
burden in EPP.
As EPP patients undergo liver transplantation for end-
stage liver disease this is reflected by MELD scores which
are comparable to patients transplanted for other diagnoses
(Freeman 2008). Although LT is associated with good
survival rates, it does not correct the underlying enzyme
defects and excessive protoporphyrin production in the
bone marrow continues (Samuel et al. 1988) leading to
almost universal recurrence of liver damage. In our series
80% of patients had histological evidence of recurrent liver
damage, of which one case is particularly advanced.
Disease recurrence was usually also reflected in a deterio-
ration in liver function tests, with a rise in bilirubin and
other markers of cholestasis. This is similar to the US
experience where 65% had recurrence and 15% required
re-transplantation (McGuire et al. 2005). Attention should
t h e r e f o r eb ef o c u s s e do ns t r a t egies to minimise the extent
of recurrent liver damage after transplantation.
Biliary complications are very common after liver
transplantation for EPP, and were observed in 80% of
patients in this cohort. A 45% biliary complication rate was
reported in the US series (McGuire et al. 2005) which,
although lower than our experience, remains significantly
higher than the reported rate of 15-30% observed in the
general liver transplant population.(Welling et al. 2008)
Biliary outflow obstruction, whether from anastomotic
strictures or disease-related accumulation of stones/sludge,
is particularly detrimental in these patients as impairment of
bile flow causes hepatic protoporphyrin accumulation and
promotes recurrence of EPP in the graft (McGuire et al.
2005). The early identification and correction of such
complications is therefore essential. One patient trans-
planted at our centre underwent Roux-en-Y biliary
reconstruction several years after transplantation follow-
ing recurrent biliary obstructive complications. This
procedure led to complete histological resolution of
biliary features, with no further biliary complications
during eight subsequent years of follow-up. Although
there is little direct experience in the setting of EPP, in
the general liver transplant population Roux-en-Y chol-
edochojejunostomy at the time of transplant has been
associated with a significantly lower rate of biliary
complications compared with conventional common duct
anastomosis.(Leonardi et al. 2005;Welling et al. 2008).
Thus we would suggest that biliary reconstruction with a
Roux loop at the time of liver transplant may further
reduce the rate of biliary complications and hence decrease
EPP-mediated liver damage in the allograft.
The occurrence of light–induced skin burns in the first
patient transplanted for EPP in our centre led to the use of
intra-operative light filters during subsequent procedures to
prevent light-induced skin and intestinal damage (McGuire
et al. 2005;Seth et al. 2007), although minor burns may still
occur (McGuire et al. 2005). However this could be
reduced by adopting a recently proposed combination of
light filters (Wahlin et al. 2008). In our experience such
filters do not cause significant distortion of vision or
interference with surgery(Seth et al. 2007).
The presence of anaemia, from haemolysis, iron defi-
ciency or chronic disease, drives the haem synthesis
pathway, further increasing the production of hepatotoxic
protoporphyrins. It is therefore recommended that adequate
haemoglobin levels (≥12 g/dl) are maintained to reduce
protoporphyrin production. Recurrent red cell transfusion
has been demonstrated to reduce erythrocyte and plasma
protoporphyrin levels in association with improvements in
photosensitivity and hepatic function, although does carry
the risk of iron overload (Dobozy et al. 1983;Spiva and
Lewis 1984;van Wijk et al. 1988;Wahlin et al. 2007). Other
therapeutic options which may be considered include
inhibiting protoporphyrin production with intravenous
hemin infusion, (Do et al. 2002), and removal of protopor-
phyrin using plasmapheresis (Do et al. 2002), and/or red
J Inherit Metab Dis (2011) 34:539–545 543cell exchange (Eichbaum et al. 2005). Both hemin infusion
and plasmapheresis have been demonstrated in a small
number of patients to improve plasma and erythrocyte
protophorphyin levels in addition to liver biochemistry and
histology(Dellon et al. 2002;Do et al. 2002;Dobozy et al.
1983;Reichheld et al. 1999). Similar improvements have
been demonstrated with red cell exchange transfusion
(Eichbaum et al. 2005) although such treatment is seldom
used and generally reserved for severe or rapidly deteriorat-
ing cases (Anstey and Hift 2007). Whilst red cell exchange
has been helpful in one of our cases with severe recurrent
EPP-mediated liver damage, plasmapheresis was not found
to be of benefit in another of the EPP patients in this cohort.
Bone marrow transplantation (BMT) is at present the
only treatment able to correct the underlying bone marrow
defect resulting in excessive protoporphyrin production
(Fontanellas et al. 2000;Wahlin et al. 2007). BMT has been
successfully used early post-transplant to stabilise or
prevent recurrent EPP liver disease (Rand et al. 2006) and,
although experience is limited, this option may be considered
in patients undergoing LT for EPP if a compatible related
donor is available. This is reinforced by survival data for
BMT for non-malignant disease, which range from a 3-year
survival rate of 70-90% in matched sibling donors to 36-65%
in unrelated donors (Appelbaum 2003), underlining the
importance of identifying sibling donors. The single BMT
undertaken in our cohort was performed one year after liver
transplantation due to rapid EPP disease recurrence. Although
BMT did cure the EPP, this patient unfortunately died
32 months later, with a fully functioning liver, from cerebral
tuberculosis related to complications of immunosuppression.
Concurrent liver and bone marrow transplantation has not to
our knowledge been attempted.
In conclusion, patients transplanted for EPP have a good
long-term survival, although given the high rate of biliary
complications and recurrent EPP-mediated liver damage we
would suggest consideration of Roux loop formation at the
time of transplant. BMT should be considered for patients
with sibling donors as this will result in cure of the EPP.
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